Filing Details
- Accession Number:
- 0002010019-26-000030
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2026-10-02 21:35:06
- Reporting Period:
- 2026-10-01
- Filing Date:
- 2026-10-02
- Accepted Time:
- 2026-10-02 21:35:06
- SEC Url:
- Form 4 Filing
- 10b5-1 trading plan:
- Yes
The filer marked this filing as including a trade under a Rule 10b5-1 trading arrangement.
A 10b5-1 plan sets trading instructions in advance, so trades follow those instructions instead of a new decision at the time of each trade. The checkbox applies to the filing as a whole and does not identify every covered trade; see the footnotes for details. It reflects the filer's disclosure, not SEC approval of the plan. SEC Form 4 instructions.
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604821 | Natera Inc. | NTRA | Services-Medical Laboratories (8071) | 010894487 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2010019 | Solomon Moshkevich | C/O Natera, Inc. 13011 Mccallen Pass Building A Suite 100 Austin TX 78753 | President, Clinicaldiagnostics | No | No | No | No |
Transaction Summary
| Sold: | 3,000 shares | Avg. Price: $414.22 | Total Value: $1,242,645.26 |
| Number of Shares After Transactions: | 106,914 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2026-10-01 | 200 | $411.62 | 109,714 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2026-10-01 | 954 | $413.11 | 108,760 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2026-10-01 | 1,846 | $415.07 | 106,914 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Hedge Fund Resource Center Billionaire Hedge Funds
